Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (201-210 of 356) with videos related to

Pageof 36
Sort By:
Biomedicines|January 28, 2026
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel PathwaysLorenzo Carriera, Roberto Lipsi, Meridiana Dodaj, et al.
The European Respiratory Journal|May 18, 2013
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway FibrosisLuca Richeldi, Harold R Collard, Roland M du Bois, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
BMJ Open Respiratory Research|January 21, 2022
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trialZoran Popmihajlov, Donna J Sutherland, Gerald S Horan, et al.
Molecular Diagnosis & Therapy|October 3, 2018
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR MutationsDaniele Magnini, Leonello Fuso, Francesco Varone, et al.
BMJ Open Respiratory Research|March 26, 2015
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacyGiacomo Sgalla, Stefania Cerri, Roberto Ferrari, et al.
Respirology (Carlton, Vic.)|May 12, 2020
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort studyMark G Jones, Christopher R T Hillyar, Anjan Nibber, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
American Journal of Clinical Pathology|November 21, 2008
Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseasesGiulio Rossi, Alessandro Andreani, Paola Morandi, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Pageof 36

Showing results (201-210 of 356) with videos related to

Sort By:
Pageof 36
Biomedicines|January 28, 2026
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel PathwaysLorenzo Carriera, Roberto Lipsi, Meridiana Dodaj, et al.
The European Respiratory Journal|May 18, 2013
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway FibrosisLuca Richeldi, Harold R Collard, Roland M du Bois, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
BMJ Open Respiratory Research|January 21, 2022
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trialZoran Popmihajlov, Donna J Sutherland, Gerald S Horan, et al.
Molecular Diagnosis & Therapy|October 3, 2018
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR MutationsDaniele Magnini, Leonello Fuso, Francesco Varone, et al.
BMJ Open Respiratory Research|March 26, 2015
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacyGiacomo Sgalla, Stefania Cerri, Roberto Ferrari, et al.
Respirology (Carlton, Vic.)|May 12, 2020
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort studyMark G Jones, Christopher R T Hillyar, Anjan Nibber, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
American Journal of Clinical Pathology|November 21, 2008
Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseasesGiulio Rossi, Alessandro Andreani, Paola Morandi, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Pageof 36